CDRH Not Surprised By NSE Letter Increase, Makes Progress On 510(k) Goals
This article was originally published in The Gray Sheet
Executive Summary
A slight uptick in not-substantially-equivalent (NSE) letters dispatched by FDA reviewers responding to 510(k) filings is not due solely to the agency's imperative to meet Medical Device User Fee & Modernization Act performance goals